A battle between financing needs and a good candidate in phase 3. I feel better that the company will reach a crossing point where the product has the upper hand and my guess within the next 12 months, lot of upside as long as financing does not have too many crushing negative repetitions. Delivering interim before calendar year ended is a feather in Simpson's cap since missing deadlines has been the delcath way, and I am banking it was predefined as to number of procedures or enrollees. I am moderately of harsh opinion about Simpson so sticking with 50 to 100 plus enrolled so far, meaning if 240 eventually reached a date of towards year end 2018 versus the planned mid 2018. Then add 1 year for data maturity, but I am giving 60 percent chance of trial will be terminated before 240 count due to stellar overall survival comparison
News 
Market Data 
Discover 
